Newsroom
CV6-168 Named Therapeutics Innovation of the Year in 2026 BioTech Breakthrough Awards
Now in Phase 1a clinical development, CV6-168 is part of CV6’s Genomic Uracil Stress Response platform, which is developing first-in-class medicines for cancer and inflammatory diseases.
CV6 Therapeutics Named Innovative Company of the Year at the 2026 AIB Business Eye Awards
The award recognizes CV6’s first-in-class therapeutic programs, while Founder and CEO Dr. Robert D. Ladner also received Highly Commended recognition for Business Personality of the Year.
CV6 Therapeutics Named Team of the Year at Belfast Chamber Business Awards
At the Belfast Chamber Business Awards, held in partnership with Bank of Ireland, CV6 won Team of the Year, sponsored by Cathedral Quarter BID, Belfast, and received Highly Commended recognition for CV6-168 in Business Innovation, sponsored by Kingsbridge Healthcare Group.
CV6 Therapeutics Founder Shortlisted for Business Post CEO of the Year Award
Dr. Robert D. Ladner has been shortlisted alongside nine business leaders from across the island of Ireland after building CV6 into a GUSR platform company whose first-in-class lead oncology candidate is advancing through a first-in-human Phase 1a clinical trial.
AIB Business Eye Award Nominations Recognise CV6 Innovation, Growth and Leadership
Organized by Northern Ireland business magazine Business Eye in partnership with AIB, the awards are marking their 20th year of recognizing achievement, innovation and leadership across the region’s business community.
HIRANI Spotlights CV6’s Belfast Biotechnology Story
From Discovery to Clinical Development: CV6 grew from an original scientific idea into a clinical-stage biotechnology company, the Northern Ireland ecosystem supporting that journey, and the company’s work across cancer and inflammatory disease.